Breast cancer subtypes and response to docetaxel in node-positive breast cancer: Use of an immunohistochemical definition in the BCIRG 001 trial

Journal of Clinical Oncology

Volumn 27, Issue 8, 2009, Pages 1168-1176

  Hugh, Judith ^a   Hanson, John ^b   Cheang, Maggie Chon U ^b   Nielsen, Torsten O ^b   Perou, Charles M ^b   Dumontet, Charles ^b   Reed, John ^b   Krajewska, Maryla ^b   Treilleux, Isahelle ^b   Rupin, Matthieu ^b   Magherini, Emmanuelle ^b   Mackey, John ^b   Martin, Miguel ^b   Vogel, Charles ^b  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EARLY CANCER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUMINAL SUBTYPE A; LUMINAL SUBTYPE B; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TAMOXIFEN; TAXOIDS;

EID: 62549091454     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.1024     Document Type: Article

References (48)

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
2. Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313, 2005
3. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000
4. Dinh P, Sotiriou C, Piccart MJ: The evolution of treatment strategies: Aiming at the target. Breast 16:S10-S16, 2007 (suppl 2)
5. Chang HY, Nuyten DS, Sneddon JB, et al: Robustness, scalability, and integration of a wound-esponse gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 102:3738-3743, 2005
6. Paik S, Shak S, Tang G, et al: A multigeneassay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004
7. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in indepen-dent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423, 2003
8. Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100:10393-10398, 2003
9. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
10. Fan C, Oh DS, Wessels L, et al: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355:560-569, 2006
11. Sotiriou C, Wirapati P, Loi S, et al: Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262-272, 2006
12. Gruvberger S, Ringner M, Chen Y, et al: Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61:5979-5984, 2001
13. Kreike B, van Kouwenhove M, Horlings H, et al: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9:R65, 2007
14. Desmedt C, Haibe-Kains B, Wirapati P, et al: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158-5165, 2008
15. Hu Z, Fan C, Oh DS, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7:96, 2006
16. Rouzier R, Perou CM, Symmans WF, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685, 2005
17. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med 131:18, 2007
18. Dalton LW, Page DL, Dupont WD: Histologic grading of breast carcinoma: A reproducibility study. Cancer 73:2765-2770, 1994
19. Frierson HF Jr, Wolber RA, Berean KW, et al: Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 103:195-198, 1995
20. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-9072, 2005
21. Badve SS, Baehner FL, Gray RP, etal: Estrogen-and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 26:2473-2481, 2008
22. Francis GD, Dimech M, Giles L, et al: Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: Results of the RCPA Quality Assurance Program. J Clin Pathol 60:1277-1283, 2007
23. Rhodes A, Jasani B, Barnes DM, et al: Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: Interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 53:125-130, 2000
24. Hayes DF, Thor AD, Dressier LG, et al: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496-1506, 2007
25. Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334, 2007
26. Baselga J, Perez EA, Pienkowski T, et al: Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer. Oncologist 11:4-12, 2006 (suppl 1)
27. Cheang MC, Voduc D, Bajdik C, et al: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368-1376, 2008
28. Jones C, Ford E, Gillett C, et al: Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res 10:5988-5997, 2004
29. Livasy CA, Karaca G, Nanda R, et al: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19:264-271, 2006
30. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502, 2006
31. Di Leo A, Claudino WM, Pestrin M, et al: Using specific cytotoxics with a targeted mind. Breast 16:S120-S126, 2007 (suppl 2)
32. Haibe-Kains B, Desmedt C, Sotiriou C, et al: A comparative study of survival models for breast cancer prognostication based on microarray data: Does a single gene beat them all? Bioinformatics 24:2200-2208, 2008
33. Meyer JS, Alvarez C, Minkowski C, et al: Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: Reproducibility of grade and advantages of proliferation index. Mod Pathol 18:1067-1078, 2005
34. Simpson PT, Reis-Filho JS, Gale T, et al: Molecular evolution of breast cancer. J Pathol 205: 248-254, 2005
35. Buerger H, Simon R, Schafer KL, et al: Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast. Mol Pathol 53:118-121, 2000
36. Martin M, Mackey J, Vogel C: Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. Breast 16:S127-S131, 2007 (suppl 2)
37. Martin M, Rodriguez-Lescure A, Ruiz A, et al: Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 100:805-814, 2008
38. Andre F, Broglio K, Roche H, et al: Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: Results from a pooled analysis. J Clin Oncol 26:2636-2643, 2008
39. Goldstein LJ, O'Neill A, Sparano JA, et al: Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 26:4092-4099, 2008
40. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
41. 53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 10:R30,2008
42. Miller ML, Ojima I: Chemistry and chemical biology of taxane anticancer agents. Chem Rec 1:195-211, 2001
43. Jacquemier J, Penault-Llorca F, Mnif H, et al: Identification of a basal-like subtype and comparative effect of epirubicin-based chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial: 33 markers studied on tissue-microarrays (TMA). J Clin Oncol 24:5s, 2006 (suppl; abstr 509)
44. Sparano JA, Paik S: Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26:721-728, 2008
45. Cardoso F, Van't Veer L, Rutgers E, et al: Clinical application of the 70-gene profile: The MINDACT trial. J Clin Oncol 26:729-735, 2008
46. Thomssen C, Vetter M, Guerts A, et al: Istumor-biological risk-assessment realistic in node-negative breast cancer? A status report of the ongoing clinical multicenter trial NNBC 3-Europe: SABCS 2006. Breast Cancer Res Treat 100:S114, 2006 (abstr 2100; suppl 1)
47. Jones SE, Erban J, Overmoyer B, et al: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542-5551, 2005
48. Hudis C, McArthur H, Dang C: Current status of the taxanes as adjuvant therapy for breast cancer. Breast 16:S132-S135, 2007 (suppl 2)